Anzeige
30.06.2023 | Practical Issues and Updates
Manage androgenetic alopecia in men with established options but emerging therapies show promise
Erschienen in: Drugs & Therapy Perspectives | Ausgabe 8/2023
Einloggen, um Zugang zu erhaltenAbstract
Androgenetic alopecia (AGA) is the most common type of hair loss disorder and affects both men and women. It is characterized by the progressive miniaturization of hair follicles in androgenetic areas of the scalp resulting in a decrease in hair density. While the number of options for managing AGA has increased over the years, evidence-based information and guidelines are limited. Treatments range from the approved and off-label use of pharmacological agents [including oral 5α-reductase inhibitors (e.g. dutasteride) and vasodilators (e.g. topical minoxidil)] to non-pharmacological treatments (e.g. low-level laser therapy) and emerging investigational therapies (e.g. botulinum toxin).